Noble Capital Markets Emerging Growth Virtual Equity Conference – October 2026 – Presenting Company Replays

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has...

Stocks are at records, credit markets are showing strain, and small caps are in the middle of the debate. The picture is more mixed than the headlines suggest.

The S&P 500...

Q1 expectations reset. We are lowering our fiscal Q1 revenue and adj. EBITDA forecasts to $299.0 million and $72.5 million, down from $307.0 million and $77.0 million, respectively. The revision...